All issues

The given work is devoted to the comparison of two tests for homogeneity: chi-square test based on contingency tables of 2 × 2 and test for homogeneity based on asymptotic distributions of the summarized square error of a distribution function estimators in the model of ”dose–effect” dependence. The evaluation of test power is performed by means of computer simulation. In order to design efficiency functions the method of kernel regression estimator based on Nadaray–Watson estimator is used.

In Russian medicine two radiopharmaceuticals are currently used for radionuclide therapy of bone metastases: ⁸⁹Sr-chloride and ¹⁵³Sm-oxabifor. The first one has many side effects, so its use is limited. The second one is available only in clinics, its transportation to which does not take much time. Currently, the third radiopharmaceutical ¹⁸⁸Re-solerene is undergoing clinical trials. Due to the generator method of obtaining ¹⁸⁸Re, this radiopharmaceutical should become available for use in many regions of our country. Therefore, there is a need for a comparative analysis of the characteristics of these radiopharmaceuticals, including on the basis of mathematical modeling.

The article discusses the features of mathematical modeling the kinetics of osteotropic radiopharmaceutical drugs in the human body with bone metastases. Based on the four-compartment model, a complex of modeling and calculation of pharmacokinetic and dosimetric characteristics of radiopharmaceuticals for radionuclide therapy of bone metastases was developed and tested. Using clinical data, the transport constants of the model were identified and the individual characteristics of Russian radiopharmaceuticals labeled ⁸⁹Sr, 153Sm and ¹⁸⁸Re were calculated (effective half-lives, maximum activity in the compartments and the times of their achievement, absorbed doses to bone tissue and metastases, endosteal bone layer, red bone marrow, blood, kidneys and bladder). The time activity dependencies for all compartments of the model are obtained and analyzed. A comparative analysis of the pharmacokinetics and dosimetry of three radiopharmaceuticals (⁸⁹Sr-chloride, ¹⁵³Sm-oxabiphore, ¹⁸⁸Re-solerene) was carried out.

From a comparative analysis of the pharmacokinetic and dosimetric characteristics of these radiopharmaceutical drugs, it follows that the best of them for widespread use in many regions of our country should be ¹⁸⁸Re-solerene, taking into account the generator method of obtaining ¹⁸⁸Re in a hospital.

Optimization of antitumor radiotherapy represents an urgent issue, as approximately half of the patients diagnosed with cancer undergo radiotherapy during their treatment. Proton therapy is potentially more efficient than traditional X-ray radiotherapy due to fundamental differences in physics of dose deposition, leading to better targeting of tumors and less collateral damage to healthy tissue. There is increasing interest in the use of non-radioactive radiosensitizing tumor-specific nanoparticles the use of which can boost the performance of proton therapy. Such nanoparticles are small volumes of a sensitizer, such as boron-10 or various metal oxides, enclosed in a polymer layer containing tumor-specific antibodies, which allows for their targeted delivery to malignant cells. Furthermore, a combination of proton therapy with antiangiogenic therapy that normalizes tumor-associated microvasculature may yield further synergistic increase in overall treatment efficacy.

We have developed a spatially distributed mathematical model simulating the growth of a non-invasive tumor undergoing treatment by fractionated proton therapy with nanosensitizers and antiangiogenic therapy. The modeling results suggest that the most effective way to combine these treatment modalities should strongly depend on the tumor cells’ proliferation rate and their intrinsic radiosensitivity. Namely, a combination of antiangiogenic therapy with proton therapy, regardless of whether radiosensitizing nanoparticles are used, benefits treatment efficacy of rapidly growing tumors as well as radioresistant tumors with moderate growth rate. In these cases, administration of proton therapy simultaneously with antiangiogenic drugs after the initial single injection of nanosensitizers is the most effective option among those analyzed. Conversely, for slowly growing tumors, maximization of the number of nanosensitizer injections without antiangiogenic therapy proves to be a more efficient option, with enhancement in treatment efficacy growing with the increase of tumor radiosensitivity. However, the results also show that the overall efficacy of proton therapy is likely to increase only modestly with the addition of nanosensitizers and antiangiogenic drugs.